XtalPi Raises Over HK$3 Billion in Less Than a Month to Accelerate AI-Driven Drug and Material Innovation

　　【Pharmaceutical Network Enterprise NewsOn February 19, AI pharmaceutical company XtalPi announced that it plans to sell up to 342 million shares at HK$6.10 per share, raising HK$2.088 billion.
 

Notably, this round of funding by XtalPi comes less than a month after the previous one. According to reports, on January 19 this year, XtalPi had just announced that on January 18, the company successfully raised approximately HKD 1.13 billion through the allotment of 264 million shares. On January 24, XtalPi Holdings Limited issued another announcement stating it had allotted 264 million new shares to no fewer than six placees, generating net proceeds of approximately HKD 1.125 billion from the placement.
 

Currently, the amount of funds raised by XtalPi through its rights issue has exceeded the proceeds from its IPO. The company was listed on the Hong Kong Main Board on June 13, 2024, raising HK$989 million at the time. Including additional proceeds from the partial exercise of the over-allotment option, it raised a total of approximately HK$1.036 billion.
 

On the surface, XtalPi has accumulated a certain amount of cash. So why has it raised funds multiple times? Industry insiders believe that this may be related to the practical application of large models and the rise of the AI pharmaceuticals boom. The prospectus shows that XtalPi mainly adopts first-principles calculations based on quantum physics, artificial intelligence, high-performance cloud computing, andRobotCombined with automation to provide services such as drug research and development for pharmaceutical companies.
 

Amid the current wave of pharmaceutical companies leveraging emerging technologies such as AI and big data to further enhance R&D efficiency and precision, and drive technological innovation, XtalPi has achieved better-than-expected progress in new businesses like antibodies and novel materials. The new round of financing will support the company in exploring new business and commercial opportunities, driving deeper engagement in AI applications for vertical fields such as drug discovery and novel materials—facilitating collaboration and the implementation of new use cases. It will also continue to empower innovation at its source, further expanding the company’s investment and incubation ecosystem.
 

At present, XtalPi's investments and collaborations in vertical fields such as AI + pharmaceuticals have started to accelerate. On February 4, XtalPi announced that it had signed a strategic cooperation agreement worth tens of millions of RMB with JW Pharmaceutical, a South Korean pharmaceutical company. XtalPi will provide JW with an automated drug discovery workstation and an AI-based chemical reaction optimization platform to comprehensively enhance the efficiency, reproducibility, and success rate of JW's drug research and development.
 

On February 19, XtalPi Holdings Limited announced that it plans to collaborate with Guangdong Hengjian Investment Holding Co., Ltd. (hereinafter referred to as "Hengjian Holding Company") to jointly select a site and launch the Greater Bay Area "Artificial Intelligence+" Technology and Industry Integration Innovation Consortium project.
 

It is estimated in the industry that in recent years, "AI + new drug" and "AI + new materials" are growing into trillion-level industry tracks. Against this market background, the future development of XtalPi is highly anticipated.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.